Relora contains a patented extract of Magnolia officinalis and a proprietary extract of Phellodendron amurenese - both plant species that have been used in Chinese medicine for 1500 years.
It was launched to the dietary supplement market in 2002 and was initially marketed as a "safe alternative to kava", working on the receptors of the central nervous system to reduce stress response without sedation.
The new delivery form means that it can now be used in bars, cookies, powders for drinks, and other products.
"As more and more people become aware of the wide-ranging effects of tension and anxiety, they will be searching for preventative options such as Relora," said director of sales Deanne Dolnick.
For instance, metabolic syndrome, collection of symptoms associated with a higher risk of diabetes and cardiovascular disease, has been associated with stress and the hormone cortisol.
Dolnick added that the new delivery form will allow manufacturers to increase sales through the development of products using Relora, or its addition to existing products.
The ingredient was developed over a four-year period, in which the company screened fractions from plants around the world, conducted pharmacology and toxicology studies and ran human trials.